Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) | MicrobiomeTrials← Back to trialsNCT03280888
Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML)
RecruitingOBSERVATIONAL
Trial Details
Start: 2014-11-05Est. Completion: 2027-11-05
Enrollment target: 50 participants Locations- CHU de Nice, Nice, France
Other microbiome trials you might be interested in
Acute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionChronic Myelomonocytic LeukemiaMyelodysplastic Syndrome With Excess BlastsRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Lymphoblastic LeukemiaRefractory Acute Myeloid LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory Mixed Phenotype Acute LeukemiaHematopoietic and Lymphoid Cell Neoplasm
This phase I/II trial studies the side effects and best dose of a radioactive agent linked to an antibody (211At-BC8-B10…
Seattle, United States
Est. completion Jan 28, 2028
Chronic Myelomonocytic LeukemiaAdvanced Myeloproliferative NeoplasmsIDH1-mutated Higher-Risk Myelodysplastic Syndromes
To learn if olutasidenib, when combined with a drug called a hypomethylating agent (HMA) can help to control MDS, CMML, …
Multiple LocationsCompleted Jun 11, 2026